LEGEND Patient = Clinical trial participant 8 mL SWFI + 1 mL 2% lidocaine immediate use Sculptra cohort (N=38) in a 96-week (2 years) extension clinical study REFERENCES Data on file
We recognize that this balance is crucial for maintaining results after completing your GLP-1 treatment
Digestive symptoms Nausea is the symptom people most often expect with appetite-focused medicines
Main results HbA1c, body weight, and FPG SGLT2i compared to placebo Four RCTs were included, with a total of 626 patients (304 in the SGLT2i group and 322 in the placebo group), which compared the changes in both HbA1c and body weight among patients with T2DM and low cardiovascular disease risk, from baseline to follow-up ( 2 = 0%) ( Figure 2A ) and body weight levels with low heterogeneity (MD: -1.32, 95% CI: -1.82, -0.82
Even before the first oral formulations, questions arose about sustainability: analysts doubt that GLP-1 prices can stay high as competition mounts ( [34] )